Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0021359 (infertility)
 26,075 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of hCG and pregnancy on the circulating levels of relaxin was investigated in 48 women undergoing in vitro fertilization and embryo transfer (ET) for the treatment of infertility. Subjects were allocated randomly to receive hCG (Profasi; 2000 IU, im) or placebo on the day of ET (day 0) and on day 3 after ET (day 3). Samples of peripheral blood were taken on days -4, 6, and 10. An additional sample was taken on day 22 from women who became pregnant. The subjects were allocated retrospectively to 1 of 4 groups: no pregnancy, no hCG (NP); pregnancy, no hCG (P); no pregnancy, hCG (NPH); and pregnancy, hCG (PH). Two patients with blighted ova and one with a tubal pregnancy were excluded from the analysis. The concentrations of relaxin were similar and rose significantly in all groups at each time point (P less than 0.05). On day 6 there was no significant difference in the increment between the groups, but by day 10, circulating levels in the P compared to the NP and those in the PH compared to the NPH group were significantly greater (P less than 0.05). By day 22 the difference between the PH and the P groups was significant (P less than 0.05). Relaxin levels correlated with progesterone levels on day 10 in the NP and P groups (r = 0.633; P less than 0.05 and r = 0.697; P less than 0.05, respectively) and with estradiol levels in the P group only on days 6 and 22 (r = 0.659; P less than 0.05 and r = 0.783; P less than 0.05, respectively). These data demonstrate that in women undergoing in vitro fertilization, relaxin levels increase during the luteal phase, and in those women who establish a pregnancy, the values are significantly greater by day 10. The administration of hCG in the early luteal phase, before implantation, to women who subsequently become pregnant significantly increased the level of circulating relaxin on day 22. The positive correlation between relaxin levels and ovarian steroid levels in the groups not receiving exogenous hCG suggests that a common factor may control the release of both.
 ...
PMID:The effect of human chorionic gonadotropin and pregnancy on the circulating level of relaxin. 202 5

Objectives of our work were to determine whether the presence of endometriosis, stage and the activity of the disease influence the sperm-peritoneal fluid (PF) incubation test and, possibly, whether a GnRH agonist (GnRHa) treatment in these patients can reduce the PF toxicity toward sperms. Preovulatory PFs from 18 patients with endometriosis (11 stage I-II rAFS and/stage III-IV; 10 with active lesions and 8 with inactive disease), and from 15 women with unexplained infertility were collected and frozen at the time of diagnostic laparoscopy. The ten patients with active endometriosis were treated by 3 months ovarian desensitization by a GnRH a (Decapeptyl 3.75 mg, Ipsen, Milan Italy) followed by a controlled ovarian hyperstimulation with a purified FSH (Metrodin, Serono, Rome, Italy) and HCG 10.000 UI (Profasi, Serono) when appropriate. In these patients, immediately before performing intrauterine and/or intraperitoneal insemination, a small aliquot of PF was collected transvaginally checking the absence of oocytes. Five hundreds suspension for one hour. PFs inducing a decrease in sperm motility greater than 20% were defined "toxic". The prevalence of toxic PF was not statistically greater in endometriosis (8/18) than in unexplained infertility (3/15) and was not dependent upon the stage of the disease, while it was significantly (rho = 0.01) more frequent in patients with active endometriosis (7/10) than other women (4/23). After a three months GnRHa treatment of these patients the rate of toxic PFs was significantly (p = 0.02) decreased (1 out of 10 treated cases).(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Sperm-peritoneal fluid incubation test: influence of a GnRH agonist treatment. 766 Jul 16